immuno oncology frontiers world miami


Aron Thall

Dr Aron Thall

Pfizer, Senior Director, Global Clinical Lead, Immuno-Oncology
After receiving a PhD in cell biology/immunology within the Cancer Research Institute of the University of California, San Francisco, Aron Thall conducted post-doctoral studies at the Howard Hughes Medical Institute of the University of Michigan, which led to key publications related to mechanisms of lymphocyte trafficking. He then moved to Boston where he worked mainly within the Harvard/MGH Transplantation Biology Research Center on a number of studies aimed at conditioning the immune system, including early work with immune-checkpoint modulation in primates, leading to multiple publications in peer reviewed journals.  From Boston he moved to IDEC Pharmaceuticals (later BiogenIDEC), where he led the clinical immunology group, focusing on cancer immunotherapies, and was involved with multiple regulatory filings for either new drugs or new indications for existing drugs. Since joining Pfizer in 2008, Aron has had increasing levels of responsibility within the Pfizer Oncology development portfolio and currently is the global clinical lead for combination immunotherapies.
  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy